Bromocriptine, a drug acting directly upon dopaminergic receptors, has been found to have a significant therapeutic action in a double-blind study of 20 patients with idiopathic Parkinsonism whE were already receiving conventional therapy, including levodopa. Neurological deficits improved by almost 20% in severely disabled patients; amelioration of mildly affected patients was about 10%. Adverse reactions were similar to those encountered with levodopa-they were all dose-dependent and reversible. These observations are discussed in relation to certain theoretical advantages which might be expected from a drug which acts directly on dopaminergic receptors.
Introduction
As a result of the introduction of levodopa many patients with Parkinsonism have derived worthwhile and at times dramatic amelioration of their motor disabilities. Nevertheless, current antiparkinsonian treatment is poorly tolerated by some 25% of patients, and in at least a further 25% the improvement achieved by optimal therapeutic regimens is limited. The advent of extracerebral decarboxylase inhibitors (Yahr, 1973) , such as carbidopa, has reduced the incidence of certain adverse reactions to levodopa, such as nausea, but many patients remain in whom severe deficits persist in spite of concerted efforts with all the antiparkinsonian drugs available at present.
One factor contributing to the failure of patients to respond well to treatment with levodopa may be the reduced striatal concentration in Parkinsonism of the enzyme responsible for converting levodopa to dopamine-L-aromatic aminoacid decarboxylase (Lloyd and Hornykiewicz, 1970) . Another possible source of difficulties is the production of active metabolites of levodopa other than dopamine-for example, noradrenaline4-which may be responsible for some of the unwanted reactions encountered in treating Parkinsonism. Both of the above drawbacks might in theory be overcome if a drug could be found which entered the brain and selectively activated dopaminergic receptors-a dopamine agonist. Such an agent could still operate when the enzymic machinery required to convert levodopa to dopamine had been destroyed by the underlying condition of Parkinsonism, and if the drug was relatively specific for dopaminergic receptors adverse effects would not be generated by activation of other synapses. The ideal antiparkinsonian drug would also have a predilection for those dopaminergic receptors which are impaired in Parkinsonism.
Clinical experience with dopaminergic agonists has not been very encouraging. Apomorphine is therapeutically active but it causes prominent emesis and has to be administered by injection (Cotzias et al., 1970) . Another dopamine agonist which has been investigated recently is piribedil, but this drug also precipitates vomiting and psychiatric adverse reactions are quite common (Vakil et al., 1973) . Bromocriptine is a new dopaminergic agonist developed to inhibit prolactin secretion (Pozo and Fliickiger, 1973) which has also been found active in animal models of Parkinsonism (Corrodi et al., 1973) . It has been used in man to suppress lactation by dopaminergic production of prolactin inhibitory factor in the hypothalamus (Pozo and Fluckiger, 1973) . We report here our experience of treating Parkinsonian patients with this drug.
Patients and Method
Twenty patients, aged 50-77 years (mean 65), with idiopathic Parkinsonism were investigated. There were 12 men and eight women. Eleven patients were receiving anticholinergic drugs and 19 were taking levodopa (mean dose 3-5 g/day), and their routine treatment was not altered.
The study was performed in three stages: (a) The dose of bromocriptine was built up to maximum tolerated intake, (b) treatment was then maintained at optimum levels for six to 12 weeks, and (c) placebo was administered for six weeks.
The initial dose of bromocriptine was 2-5 mg twice daily, and this was increased by 2-5 mg each week until unwanted effects were encountered or an arbitrary upper limit of 30 mg/day was reached. An optimum maintenance dose was established at 70%-80% of the intake which produced adverse reactions. The mean optimum dosage was found to be 18-8 mg/day (range 7 5-30), which was reached over an average period of 8-8 weeks (range 3-16).
On attaining the maximum tolerated dosage (or 30 mg/day) patients were allocated at random into one of four groups who were treated for 6, 8, 10, and 12 weeks. The variation in duration of treatment was undertaken in an effort to reduce the risk of the "blind" evaluator decoding the change to placebo.
CLINICAL EVALUATIONS
An arbitrarily defined clinical scoring protocol was employed using a scale from 0 (normality) to 4 (maximum deficit) for functional disabilities assessed from the history-washing, eating, dressing, and writing. The physical signs were evaluated after clinical examination using a similar five-point scale for walking, posture, facial expression, rising from a chair, balance, finger dexterity, rigidity, tremor, speech, and sialorrhoea.
Evaluations were performed at outpatient attendances at intervals of two weeks. The same physician performed all the clinical assessments on every patient; he was unaware of treatment regimens.
CARDIOVASCULAR OBSERVATIONS
Cardiovascular observations were made with an Arteriosonde (Roche) automatic blood pressure recorder at every outpatient attendance. The patient lay down on a couch and measurements of blood pressure and pulse rate were made after one and three minutes. The patient then stood up and after one minute the recordings were repeated. The initial findings (after lying for one minute) were discarded since the first observations were only performed as a manoeuvre to acclimatize the patient to the recording situation.
BIOCHEMICAL STUDIES
Administration of a dopaminergic agonist leads to a fall in the concentration in the cerebrospinal fluid (C.S.F.) of the major metabolite of dopamine-homovanillic acid (HVA). Changes in HVA can, therefore, facilitate the interpretation of the mechanism of drug action. Pretreatment with probenecid increases the precision of C.S.F. studies by blocking the active transport mechanism that removes HVA from the C.S.F. Biochemical studies were completed on five patients who gave informed consent for two lumbar punctures, one on placebo and the other on bromocriptine.
Levodopa therapy was stopped 48 hours before lumbar puncture. The patients remained in bed over this time and were given 6-0 g of probenecid by mouth over the 19 hours leading up to extraction of C.S.F. Bromocriptine was given in three doses of 2-5 g, given 10, eight, and six hours before lumbar puncture.
Results
The results of the last three evaluations during treatment with bromocriptine were compared with those of the three on placebo. An analysis of variance indicated that the deterioration on placebo was significant at the 0-1% level. We were interested to relate the extent of therapeutic activity of bromocriptine to the severity of Parkinsonism. The total disability scores at final assessment were therefore placed in ascending order, and the patients were divided into two groups by drawing an arbitrary line halfway down the list. The mean improvement induced by bromocriptine in the less severely disabled patients was 8-9%, while that for the more disabled group was 18-9%.
The dose was increased until adverse reactions were seen in 17 patients. Three patients reached 30 mg/day without experiencing any unwanted effects. All dose limiting problems I I 10 9. 8 7. (Farnebo and Hamberger, 1973) and a negative feed-back loop (Walters et al., 1974) . Most of our patients were taking levodopa, and presumably maintaining a certain level of therapeutic response by dopamine release. The fact that further improvement was obtained with a dopamine agonist suggests that if this drug reduces dopamine output the consequences are of minor importance. Nevertheless, it would clearly be of interest to establish the relative therapeutic potency of bromocriptine with and without concomittant administration of levodopa. Another important area for further investigation is the possible potentiation of bromocriptine by simultaneous administration of a phosphodiesterase inhibitor such as caffeine or theophylline since these agents would be expected to delay the destruction of cyclic adenosine monophosphate formed in striatal neurons as the result of dopaminergic activation (Kebabian et al., 1972) .
Introduction
The extent to which commonly used beta-blocking drugs affect airway resistance in normal adults is controversial (McNeill, 197, 1) . The relative cardiac and bronchopulmonary activity of such drugs is usally assessed 'by giving arbitrary doses of each drug and determining their effects at arbitrary fixed times after administration. Clinically, however, it may be more important to compare unwanted side effects such as broncheconstriction at times when desirable cardiac effects are similar.
Beta-adrenoceptor blocking drugs produce little or no slowing of resting heart rate but greatly reduce that during strenuous exercise (Robinson et al., 1966) . This has been taken as evidence that beta-sympathetic stimulation of the heart increases with exercise, and hence a useful index of cardiac beta-4blocking activity is how much the heart rate associated with vigorous exercise is reduced. By analogy, if the bronchodilatation accompanying exercise (Jones et al., 1962) is also due to sympathetic stimulation, the effect of
